Illinois Considers Prescription Drug Pricing Board

Illinois lawmakers are close to deciding on a bill that seeks to address prescription drug cost concerns through the creation of a state panel. This panel would evaluate drug prices and their accessibility, examining whether medications remain out of reach for those who need them most.

The planned Prescription Drug Affordability Board is part of a Democratic initiative aimed at tackling affordability issues pervading both Illinois and the wider United States. However, skeptics argue that the panel could add bureaucracy without effectively reducing drug prices.

On Wednesday, the House Executive Committee passed the bill along party lines, with a vote of 8-4. The full House will soon deliberate on this proposal. Advocates believe that the board could help control drug costs, a pressing political matter that has also received attention under recent federal initiatives, including new policies from President Biden.

Representative Nabeela Syed, a Democrat from Palatine, is the primary sponsor of the bill. She described it as “a heavily, heavily negotiated bill” during a recent committee meeting. A prior version of the bill did not advance in the House last month, but this iteration was introduced last week.

If formed, the five-member board, appointed by the governor, would assess prescription drug costs, identify unreasonably high prices, and potentially impose upper payment limits. These limits would cap the amounts consumers pay for medications. Pharmaceutical companies would have a chance to present their price rationale before any caps are enforced.

The board’s responsibilities would also include enhancing medication access, focusing on rural and low-income communities. A key aspect is linking Illinois drug prices to Medicare’s new negotiation authority established by the Inflation Reduction Act of 2022. Starting this year, Medicare has negotiated reduced prices for ten costly medications, showing noticeable savings for consumers.

For instance, the cost of a 30-day supply of Januvia, a diabetes medication, diminished from $527 to $113. Enbrel, used for rheumatoid arthritis, saw its price decrease from $7,106 to $2,355, as reported by the Centers for Medicare & Medicaid Services.

Syed’s legislation aims to have these Medicare-negotiated prices automatically set as the highest payment limits for Illinois consumers across various healthcare plans. Technical adjustments would require separate opt-ins for Medicaid and specific state employee health programs.

Anusha Thotakura, executive director of Citizen Action/Illinois, supports Syed’s initiative. Her organization’s recent study highlighted an overpayment issue, estimating that Illinois spends over $190 million more on these drugs beyond what Medicare rates suggest, despite opposition contesting these figures.

The bill requires board members to possess expertise in healthcare, pharmacy, or clinical medicine, ensuring they are not affiliated with any drug manufacturers or related trade associations. Members will serve five-year terms, with initial appointments staggered. They will receive assistance from a 15-member council formed by appointees from state leaders, including the governor, House speaker, Senate president, and minority chamber leaders.

Board decisions may face appeals and judicial reviews. The Illinois attorney general’s office has conditional enforcement authority over the board, although Rep. Syed indicated that legislative adjustments can address potential legal gaps.

A dozen states have active Prescription Drug Affordability Boards, though their comprehensiveness varies. Colorado, Minnesota, and Maryland, the first state to establish such a board in 2019, grant their boards authority to set payment ceilings on drugs.

The Pharmaceutical Research and Manufacturers of America, a critic of the Illinois proposal, claims existing boards in other states haven’t achieved meaningful cost savings for patients. According to Peter Fotos, PhRMA’s deputy VP for state advocacy, the design of the Medicare drug pricing framework wasn’t intended for state application.

Deputy Republican leader Ryan Spain of Peoria expressed concern about bureaucracy and lack of a dedicated state agency to supervise the board. “If this bill passes, we’re going to inherit this mess,” he noted, calling for alignment with a parent organization.

Rep. Syed stated that the board’s independent operation negates the need for placement within a specific state department. Operating expenses are projected at $750,000.

“Truthfully, I just don’t see the need for it to be housed in a department,” she remarked.

A spokesperson for Governor JB Pritzker did not specify his stance on the board but mentioned ongoing reviews by his office. Separately, the legislature passed another affordability-centered bill endorsed by Pritzker. The Senate voted 46-12 to ban “junk fees,” requiring price displays to include all mandatory fees and surcharges. This measure now awaits the governor’s signature.